Patient number | Biopsy | Treatment | Knee synovitis | DAS28 | Grade 3 follicles (%) | PNAd+ HEV | CXCL13 | CCL21 |
---|---|---|---|---|---|---|---|---|
DAS, Disease Activity Score; ETN, etanercept; HEV, high endothelial venules; IFX, infliximab; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PNAd, peripheral lymph node addressin. | ||||||||
*Patients 1–3 were rebiopsied at the contralateral knee with active synovitis after a mean (SD) of 25 (18) months from the first contralateral biopsy; they were receiving stable treatment. Patients 4–11 were rebiopsied at the same knee after 3 months of anti-TNFα treatment. | ||||||||
1 | Right | MTX | Yes | 6.0 | 38 | + | + | + |
Left | MTX | Yes | 5.9 | 40 | + | + | + | |
2 | Right | NSAID | Yes | 3.3 | 0 | – | – | – |
Left | NSAID | Yes | 3.4 | 0 | – | – | – | |
3 | Right | NSAID | Yes | 4.4 | 0 | – | – | – |
Left | NSAID | Yes | 3.4 | 0 | – | – | + | |
4 | First | MTX | Yes | 6.5 | 0 | – | – | – |
Second | MTX+ETN | No | 3.1 | 0 | – | – | – | |
5 | First | MTX | Yes | 4.2 | 40 | + | + | + |
Second | MTX+ETN | Yes | 3.1 | 62 | + | + | + | |
6 | First | MTX | Yes | 5.7 | 23 | + | + | + |
Second | MTX+ETN | Yes | 4.4 | 63 | + | + | + | |
7 | First | MTX | Yes | 4.5 | 13 | + | + | + |
Second | MTX+ETN | Yes | 4.3 | 49 | + | + | + | |
8 | First | NSAID | Yes | 3.5 | 25 | + | + | + |
Second | IFX | Yes | 3.3 | 40 | + | + | + | |
9 | First | MTX | Yes | 6.0 | 38 | + | + | + |
Second | MTX+ETN | No | 1.6 | 0 | – | – | – | |
10 | First | MTX | Yes | 4.7 | 57 | + | + | + |
Second | MTX+ETN | No | 1.5 | 0 | – | – | – | |
11 | First | NSAID | Yes | 4.7 | 34 | + | + | + |
Second | IFX | No | 0.7 | 0 | – | – | – |